Article Figures & Data
Figures
- Fig. 1
Experimental design of αGalCer-pulsed APC administration. *, injection of αGalCer nonpulsed APCs. The patients received αGalCer-pulsed APC containing DCs (DC#1, DC#2, DC#3, and DC#4). The timings of apheresis and DC administration are shown.
- Fig. 2
Flow cytometric analysis of αGalCer-pulsed APC (GM/IL-2 DC). A, forward scatter/side scatter (FS/SS) profiles with gates of the administered cells; dashed line, gate for B; solid line, gate for C. B, expression levels of HLA-DR, CD11c, CD86, CD83, CD80, and CD14 were assessed by flow cytometric analysis at the time of administration. Solid lines, background staining with an isotype control. Bold lines, staining profiles of the indicated molecules. Data are for three patients in the level 3 group. C, summary of the contents of cells administered. Each patient received αGalCer-pulsed APCs (GM/IL-2 DC) four times. The mean percentages of the indicated fractions in the administered cells are shown with SDs.
- Fig. 3
Points, numbers of peripheral blood Vα24 NKT cells during the course of treatment in three patients in the level 3 group. The numbers and percentages of peripheral blood Vα24 NKT cells (Vα24+Vβ11+cells) during the course of treatment in three patients in the level 3 group were assessed by flow cytometric analysis. The frequency of Vα24 NKT cells in the total PBMCs of each patients is as follows; case 009, 0.01%; case 010, 0.03%; and case 011, 0.012%.
- Fig. 4
Increased expression of IFN-γ in Vα24 NKT cells after administration of αGalCer-pulsed DCs. The ability to produce IFN-γ in peripheral blood Vα24 NKT cells during the course of treatment in case 010 was determined by quantitative reverse transcription-PCR. Whole PBMC was activated with immobilized anti-CD3ε overnight. Vα24+Vβ11+ NKT cells were sorted and quantitative reverse transcription-PCR for IFN-γ and Cα was done. Columns, relative IFN-γ mRNA (copy numbers of IFN-γ mRNA normalized to the copy numbers of TCR Cα mRNA in 100 Vα24+Vβ11+ NKT cells) for triplicate cultures; bars, SD. *, not detected.
Tables
- Table 1
Characteristics of enrolled patients
Total number entered 11 Completions/dropouts 9/2 Median age (range) 69.0 (63-78) Gender, male/female 8/3 PS, 0/1/2 9/2/0 Histology, Ad*/Sq**/large*** 9/1/1 Clinical staging, IV/recurrence 2/9 Prior treatment: surgey/radiation/chemotherapy/none 2/4/6/1 NOTE. Values represent numbers of patients.
Abbreviations: PS, performance status; Ad; adenocarcinoma; Sq, squamous cell carcinoma.
- Table 2
Patient profiles and adverse events observed
Level events (grade) Case Age/gender Diagnosis Cancer lesion Pretreatment Adverse 1 001 65/F Rec Lung OP Hot flash(I), headache(I), hyperkalemia(II), cretinine(I) 002 63/M Rec Lung None Hyperkalemia(II) 003 68/M Rec Lung CT None 2 006 65/M Rec Lung, brain, bone CT, RT Hyperbilirubinemia 007 78/M Rec Lung RT Hyperkalemia(I) 008 67/M Rec Lung RT None 3 009 61/M Primary Lung, bone, adrenal gland RT None 010 66/F Rec Lung, pleura OP, CT Headache(I), cytitis(II), general fatigue(II) 011 74/F Primary Lung, pleura, bone CT None Abbreviations: M, male; F, female; rec, recurrence; primary, primary lung cancer; ST, surgical treatment; CT, chemotherapy; RT, radiation therapy.
Volume 11, Issue 5
